CTLA4 and neoplasm: Several murine studies suggest that CTLA-4 inhibitors may reduce Treg-mediated suppression and eliminate Tregs in the tumor microenvironment (TME) through antibody-dependent cell-mediated cytotoxicity (ADCC).